Topic: How To Invest

Wall Street Stock Forecaster Hotline – Friday, August 27, 2021

Article Excerpt

PFIZER INC., $46.58, New York symbol PFE, is a buy. The company is one of the world’s largest makers of prescription drugs. Its top-selling brands include Lyrica (epilepsy), Celebrex (arthritis pain), Prevnar (pneumonia) and Enbrel (rheumatoid arthritis). Pfizer has now agreed to buy Trillium Therapeutics Inc. (Nasdaq symbol TRIL), which is developing several blood cancer treatments. Last year, the company invested $25 million in Trillium, representing about 2% of its outstanding shares. The company will now pay $2.26 billion in cash for the rest of Trillium. To put that in context, Pfizer earned $6.05 billion, or $1.07 a share, in the three months ended June 30, 2021. If Trillium shareholders approve, Pfizer expects to complete the purchase in the next few months. Trillium’s products are still in the early development stage, but Pfizer’s expertise should accelerate that process. Pfizer is a buy. Pfizer recent coverage: Hotline for July 2, 2021 May 2021 issue NORDSTROM INC., $29.22, New York symbol JWN, is still a hold. The retailer owns and…

You are trying to access subscriber-only content.

To read this article, you may subscribe or sign in.
If you are already a subscriber, log in here.

If you wish to become a subscriber, click here. Or you may enjoy access to all our publications when you become a Member of Pat McKeough's Inner Circle Pro.